Summary
"...Many targeted agents are available or under development for use in a wide range of tumors. The inhibition of a single signal-transduction pathway is unlikely to provide optimal results, and therefore a combination of agents appears to be a valid strategy. Our results, however, argue against the combined use of anti-VEGF and anti-EGFR monoclonal antibodies with chemotherapy in cases of metastatic colorectal cancer."
Analysis
Good intuitive concept but this is a good example that concepts can be disproven when "the rubber hits the road" in a good clinical trial. See the accompanying editorial:
http://content.nejm.org/cgi/content/full/360/6/623
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
